Stay updated on INSIGHT 2: Tepotinib+Osimertinib in MET+ NSCLC Clinical Trial
Sign up to get notified when there's something new on the INSIGHT 2: Tepotinib+Osimertinib in MET+ NSCLC Clinical Trial page.

Latest updates to the INSIGHT 2: Tepotinib+Osimertinib in MET+ NSCLC Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedRevision note updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check17 days agoChange DetectedUpdate timestamps were added (2026-02-27, 2026-02-26, 2026-02) and older timestamps (2025-12-12, 2025-11-28, 2025-11) were removed from the page.SummaryDifference0.1%

- Check32 days agoChange DetectedThe site version has been updated from v3.4.1 to v3.4.2; no user-facing changes to the study details page were observed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check40 days agoChange DetectedThe change is a backend revision update (v3.4.1 added, v3.4.0 removed) with no visible changes to study content or layout. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check47 days agoChange DetectedAdded a Show glossary option and updated metadata labels (Last Update Submitted that Met QC Criteria; No FEAR Act Data) with a revision note of v3.4.0, while removing the previous capitalization variant and the No FEAR Act data label.SummaryDifference0.1%

- Check54 days agoChange DetectedThe update timestamp label changed from 'Last Update Posted (Estimated)' to 'Last Update Posted'. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

Stay in the know with updates to INSIGHT 2: Tepotinib+Osimertinib in MET+ NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the INSIGHT 2: Tepotinib+Osimertinib in MET+ NSCLC Clinical Trial page.